 Scott Kono
Concepts (129)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Squamous Cell | 9 | 2022 | 643 | 0.640 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 6 | 2013 | 1186 | 0.490 |
Why?
| | Head and Neck Neoplasms | 7 | 2014 | 562 | 0.470 |
Why?
| | Lung Neoplasms | 7 | 2022 | 2660 | 0.430 |
Why?
| | Receptors, Fibroblast Growth Factor | 2 | 2011 | 70 | 0.370 |
Why?
| | ErbB Receptors | 5 | 2013 | 632 | 0.300 |
Why?
| | Lymph Node Excision | 1 | 2009 | 173 | 0.270 |
Why?
| | Lymphatic Metastasis | 1 | 2009 | 334 | 0.270 |
Why?
| | Empyema, Pleural | 1 | 2007 | 13 | 0.250 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2014 | 1961 | 0.200 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2009 | 881 | 0.200 |
Why?
| | Quinazolines | 2 | 2013 | 266 | 0.170 |
Why?
| | Biosimilar Pharmaceuticals | 1 | 2021 | 28 | 0.170 |
Why?
| | Antineoplastic Agents | 2 | 2009 | 2201 | 0.170 |
Why?
| | Pyrazoles | 2 | 2013 | 512 | 0.150 |
Why?
| | Sulfonamides | 2 | 2013 | 579 | 0.150 |
Why?
| | Receptor Protein-Tyrosine Kinases | 2 | 2011 | 230 | 0.140 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2021 | 299 | 0.140 |
Why?
| | Sirolimus | 2 | 2014 | 280 | 0.110 |
Why?
| | Neoplasm Staging | 4 | 2015 | 1465 | 0.110 |
Why?
| | Multi-Institutional Systems | 1 | 2014 | 6 | 0.110 |
Why?
| | Adenocarcinoma | 2 | 2013 | 923 | 0.110 |
Why?
| | SEER Program | 2 | 2013 | 226 | 0.100 |
Why?
| | Carboplatin | 1 | 2014 | 161 | 0.100 |
Why?
| | Social Class | 1 | 2015 | 265 | 0.100 |
Why?
| | Chemoprevention | 1 | 2013 | 91 | 0.100 |
Why?
| | Paranasal Sinus Neoplasms | 1 | 2013 | 29 | 0.100 |
Why?
| | Neoplasm Metastasis | 2 | 2014 | 691 | 0.100 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 2013 | 82 | 0.090 |
Why?
| | Complementary Therapies | 1 | 2013 | 95 | 0.090 |
Why?
| | Maintenance Chemotherapy | 1 | 2012 | 42 | 0.090 |
Why?
| | Carcinoma, Adenoid Cystic | 1 | 2012 | 19 | 0.090 |
Why?
| | Oropharyngeal Neoplasms | 1 | 2012 | 55 | 0.090 |
Why?
| | Thyroid Neoplasms | 1 | 2015 | 349 | 0.090 |
Why?
| | Autocrine Communication | 1 | 2011 | 38 | 0.080 |
Why?
| | Carcinoma, Large Cell | 1 | 2011 | 17 | 0.080 |
Why?
| | Middle Aged | 12 | 2015 | 35971 | 0.080 |
Why?
| | Gene Rearrangement | 1 | 2011 | 155 | 0.080 |
Why?
| | Signal Transduction | 3 | 2013 | 5185 | 0.070 |
Why?
| | Radiotherapy | 1 | 2009 | 205 | 0.070 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2014 | 990 | 0.070 |
Why?
| | Biomedical Research | 1 | 2014 | 712 | 0.070 |
Why?
| | Papillomavirus Infections | 1 | 2012 | 342 | 0.070 |
Why?
| | Genetic Testing | 1 | 2010 | 480 | 0.070 |
Why?
| | Humans | 19 | 2022 | 144667 | 0.060 |
Why?
| | Thoracic Surgery, Video-Assisted | 1 | 2007 | 48 | 0.060 |
Why?
| | Pleural Effusion | 1 | 2007 | 59 | 0.060 |
Why?
| | Biomarkers, Tumor | 2 | 2013 | 1319 | 0.060 |
Why?
| | Combined Modality Therapy | 1 | 2009 | 1268 | 0.060 |
Why?
| | Radiography | 1 | 2007 | 848 | 0.050 |
Why?
| | Protein Kinase Inhibitors | 1 | 2010 | 971 | 0.050 |
Why?
| | Celecoxib | 2 | 2013 | 41 | 0.050 |
Why?
| | Survival Rate | 3 | 2013 | 2089 | 0.050 |
Why?
| | Erlotinib Hydrochloride | 2 | 2013 | 72 | 0.050 |
Why?
| | Everolimus | 2 | 2014 | 112 | 0.050 |
Why?
| | Incidence | 3 | 2015 | 2892 | 0.050 |
Why?
| | Oxazepines | 1 | 2022 | 5 | 0.050 |
Why?
| | Male | 11 | 2015 | 72431 | 0.040 |
Why?
| | Filgrastim | 1 | 2021 | 13 | 0.040 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2022 | 52 | 0.040 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2022 | 108 | 0.040 |
Why?
| | Infliximab | 1 | 2021 | 111 | 0.040 |
Why?
| | Female | 10 | 2015 | 78304 | 0.040 |
Why?
| | United States Food and Drug Administration | 1 | 2021 | 205 | 0.040 |
Why?
| | Aged | 7 | 2014 | 25955 | 0.040 |
Why?
| | Imidazoles | 1 | 2022 | 246 | 0.040 |
Why?
| | United States | 4 | 2022 | 16018 | 0.040 |
Why?
| | Aged, 80 and over | 4 | 2013 | 8284 | 0.040 |
Why?
| | In Situ Hybridization, Fluorescence | 2 | 2011 | 323 | 0.040 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2022 | 380 | 0.040 |
Why?
| | Prognosis | 3 | 2013 | 4312 | 0.040 |
Why?
| | Pilot Projects | 2 | 2014 | 1886 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2012 | 11735 | 0.030 |
Why?
| | Anti-Bacterial Agents | 1 | 2007 | 1928 | 0.030 |
Why?
| | Michigan | 1 | 2015 | 137 | 0.030 |
Why?
| | Adult | 6 | 2014 | 40489 | 0.030 |
Why?
| | Demography | 1 | 2015 | 287 | 0.030 |
Why?
| | Health Maintenance Organizations | 1 | 2014 | 105 | 0.030 |
Why?
| | Maximum Tolerated Dose | 1 | 2014 | 211 | 0.030 |
Why?
| | Cetuximab | 1 | 2014 | 111 | 0.030 |
Why?
| | Ethmoid Sinus | 1 | 2013 | 6 | 0.020 |
Why?
| | Maxillary Sinus Neoplasms | 1 | 2013 | 7 | 0.020 |
Why?
| | Immunoenzyme Techniques | 1 | 2013 | 197 | 0.020 |
Why?
| | Taxoids | 1 | 2013 | 116 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2014 | 768 | 0.020 |
Why?
| | Follow-Up Studies | 2 | 2013 | 5414 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2014 | 779 | 0.020 |
Why?
| | Survival Analysis | 1 | 2015 | 1370 | 0.020 |
Why?
| | Submandibular Gland Neoplasms | 1 | 2012 | 1 | 0.020 |
Why?
| | Parotid Neoplasms | 1 | 2012 | 15 | 0.020 |
Why?
| | Salivary Gland Neoplasms | 1 | 2012 | 39 | 0.020 |
Why?
| | Tumor Cells, Cultured | 1 | 2013 | 881 | 0.020 |
Why?
| | Mice, Nude | 1 | 2013 | 677 | 0.020 |
Why?
| | Organoplatinum Compounds | 1 | 2011 | 66 | 0.020 |
Why?
| | Pemetrexed | 1 | 2011 | 39 | 0.020 |
Why?
| | Glutamates | 1 | 2011 | 66 | 0.020 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2011 | 93 | 0.020 |
Why?
| | Recurrence | 1 | 2014 | 1136 | 0.020 |
Why?
| | Guanine | 1 | 2011 | 85 | 0.020 |
Why?
| | DNA, Neoplasm | 1 | 2011 | 158 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2013 | 967 | 0.020 |
Why?
| | Blotting, Western | 1 | 2013 | 1161 | 0.020 |
Why?
| | ras Proteins | 1 | 2011 | 151 | 0.020 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2011 | 254 | 0.020 |
Why?
| | Cell Cycle | 1 | 2013 | 595 | 0.020 |
Why?
| | Mutation | 2 | 2011 | 4081 | 0.020 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2013 | 452 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2013 | 1537 | 0.020 |
Why?
| | Structure-Activity Relationship | 1 | 2010 | 564 | 0.020 |
Why?
| | Pharmacogenetics | 1 | 2010 | 172 | 0.020 |
Why?
| | Cell Movement | 1 | 2013 | 959 | 0.020 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2011 | 431 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2012 | 1705 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2011 | 1047 | 0.020 |
Why?
| | Proto-Oncogene Proteins | 1 | 2011 | 619 | 0.020 |
Why?
| | Registries | 1 | 2015 | 2392 | 0.020 |
Why?
| | Disease Progression | 1 | 2013 | 2847 | 0.010 |
Why?
| | Qualitative Research | 1 | 2013 | 1668 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2013 | 2489 | 0.010 |
Why?
| | Retrospective Studies | 2 | 2015 | 17149 | 0.010 |
Why?
| | Apoptosis | 1 | 2013 | 2397 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2011 | 3523 | 0.010 |
Why?
| | Risk Factors | 1 | 2015 | 10796 | 0.010 |
Why?
| | Quality of Life | 1 | 2012 | 3183 | 0.010 |
Why?
| | Mice | 1 | 2013 | 18261 | 0.010 |
Why?
| | Young Adult | 1 | 2012 | 14122 | 0.010 |
Why?
| | Adolescent | 1 | 2012 | 22409 | 0.010 |
Why?
| | Child | 1 | 2012 | 22600 | 0.010 |
Why?
| | Animals | 1 | 2013 | 37948 | 0.000 |
Why?
|
|
Kono's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|